Beigene (NASDAQ:ONC) Price Target Raised to $313.00 at Macquarie

Beigene (NASDAQ:ONC) had its price objective lifted by stock analysts at Macquarie from $259.00 to $313.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Macquarie’s price objective suggests a potential upside of 16.10% from the stock’s current price.

Beigene Stock Down 3.2 %

NASDAQ:ONC traded down $8.79 during mid-day trading on Friday, hitting $269.59. 428,311 shares of the company’s stock were exchanged, compared to its average volume of 406,418. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene has a fifty-two week low of $126.97 and a fifty-two week high of $287.88. The company has a market cap of $26.38 billion, a PE ratio of -32.72, a P/E/G ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. On average, research analysts anticipate that Beigene will post -5.82 earnings per share for the current year.

Insider Activity

In related news, SVP Chan Henry Lee sold 1,202 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Lai Wang sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $257.23, for a total transaction of $1,286,150.00. Following the completion of the transaction, the insider now owns 920,920 shares in the company, valued at approximately $236,888,251.60. This trade represents a 0.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 58,123 shares of company stock worth $14,081,527 over the last ninety days. Company insiders own 7.43% of the company’s stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.